Cell therapy (CAR-T) · Kills target cells, directed at CD4 · developed by Legend Biotech USA
LB1901 is an autologous CAR-T cell therapy made from a patient's own T-lymphocytes, transduced with a lentiviral vector to express a chimeric antigen receptor targeting CD4. The modified cells bind CD4-expressing tumor cells and selectively kill them. It is studied in T-cell lymphomas, including peripheral and cutaneous forms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04712864 | Phase 1 | T-Cell Lymphoma | Unknown | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cutaneous T-Cell Lymphoma RecurrentCutaneous T-Cell Lymphoma RefractoryPeripheral T-Cell Lymphoma RecurrentPeripheral T-Cell Lymphoma RefractoryT-Cell Lymphoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.
See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LEGN catalysts and pipeline →